Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 7, 2026; 32(21): 116467
Published online Jun 7, 2026. doi: 10.3748/wjg.v32.i21.116467
Published online Jun 7, 2026. doi: 10.3748/wjg.v32.i21.116467
Letter to the Editor: Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy
Sheng Xu, Guang-Rong Lu, Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Zheng Zhu, Pei-Hong Shi, Yue-Ting Xu, Hui-Ming Zhang, Yang Zheng, The Second School of Medicine, Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Yi-Tong Chen, The First School of Medicine, Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Bin-Jiao Zheng, Key Laboratory of Laboratory Medicine of the Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Bin-Jiao Zheng, Department of Cell Biology and Genetics, School of Basic Medical Sciences, University of South China, Hengyang 421001, Hunan Province, China
Bin-Jiao Zheng, Department of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan Province, China
Co-first authors: Sheng Xu and Zheng Zhu.
Co-corresponding authors: Guang-Rong Lu and Bin-Jiao Zheng.
Author contributions: Xu S and Zhu Z contributed to manuscript writing and editing; Zhang HM performed the literature search; Xu YT and Shi PH created the outline of the manuscript; Zheng Y and Chen YT supervised the study; Lu GR and Zheng BJ contributed to conceptualization and critical revisions; Xu S and Zhu Z contributed equally to this work as co- first authors; Lu GR and Zheng BJ contributed equally to this work as co-corresponding authors; all authors have read and approved the final manuscript.
AI contribution statement: During the preparation of this manuscript, the authors used Doubao (a Chinese AI tool), solely for language polishing, translation, and text simplification to meet the journal's word count and language quality requirements. All content was independently composed, reviewed, and verified by the authors to ensure scientific accuracy, originality, and proper referencing. No AI tool was used for study design, data analysis, or interpretation of results. The authors take full responsibility for the entire content of the manuscript.
Supported by Zhejiang Medical and Health Science and Technology Plan Project, No. 2023KY910; and Project of Special Research Funds for Clinical Medicine of Zhejiang Medical Association, No. 2023ZYC-A124.
Conflict-of-interest statement: The authors declare no conflict of interest.
Corresponding author: Bin-Jiao Zheng, PhD, Key Laboratory of Laboratory Medicine of the Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, University Town, Chashan, Wenzhou 325000, Zhejiang Province, China. gusdy13x@wmu.edu.cn
Received: November 12, 2025
Revised: January 22, 2026
Accepted: February 6, 2026
Published online: June 7, 2026
Processing time: 195 Days and 15.2 Hours
Revised: January 22, 2026
Accepted: February 6, 2026
Published online: June 7, 2026
Processing time: 195 Days and 15.2 Hours
Core Tip
Core Tip: Gastric cancer (GC) needs more precise therapies, and Si et al’s study presents promising insights by revealing that the N6-methyladenosine (m6A) reader IGF2BP3 drives GC progression through an m6A-dependent post-transcriptional mechanism. This fills the long-standing gap in understanding the downstream targets of IGF2BP3 in GC and, for the first time, links the IGF2BP3/FBXO32 axis to the cyclic guanosine monophosphate-protein kinase G pathway. Additionally, it promotes discussions on the role of m6A in tumorigenesis and points to critical directions such as mechanistic exploration, tumor microenvironment crosstalk and subtype-specific research, laying key groundwork for translating this axis into GC clinical treatment.